Want to see GLMD full AI Analyst Report?
GLMD Stock Chart & Stats
$0.79
-$0.05(-1.56%)
At close: 4:00 PM EST
$0.79
-$0.05(-1.56%)
Day’s Range― - ―
52-Week Range$0.41 - $2.09
Previous CloseN/A
Volume19.24K
Average Volume (3M)84.25K
Market Cap
$3.95M
Enterprise Value-$11.64
Total Cash (Recent Filing)$15.45M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Jul 30, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding7,684,074
10 Day Avg. Volume86,643
30 Day Avg. Volume84,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.56
Revenue Forecast (FY)$5.72M
Bulls Say, Bears Say
Bulls Say
Low LeverageEffectively zero debt materially reduces refinancing and interest-rate risk for a development-stage biotech. With limited leverage, management has more optionality to deploy capital for R&D, M&A, or commercialization without near-term debt-servicing constraints, improving resilience over 2–6 months.
Acquisition Adds Commercial-stage AssetAdding Colospan's CG-100 creates immediate commercial revenue potential and diversifies Galmed from purely clinical-stage drug development toward a unified GI platform. This structural shift increases near-term revenue visibility and builds in commercialization expertise that can support longer-term scale.
Improved Drug FormulationA fivefold bioavailability gain and GMP clinical batch readiness meaningfully de-risks clinical development and may lower manufacturing cost per dose. Better exposure increases probability of achieving therapeutic endpoints, supports broader indications, and can extend IP and commercial competitiveness.
Bears Say
No Revenue And Persistent LossesA zero-revenue base with recurring net losses means Galmed remains fully dependent on pipeline progress and external funding. Without predictable product cash flows, margins and long-term viability hinge on successful trials or deals, leaving material execution and financing risk over the medium term.
Negative Operating Cash FlowConsistent negative operating and free cash flow—despite prior improvement—means ongoing cash burn that will require fresh capital absent revenue. Free cash flow tracking net loss signals limited non-cash offsets and elevates dilution or financing timing risk over the next several quarters.
Acquisition Execution And Contingent CostsBuying a company with going-concern issues and committing capital plus contingent earnouts reshapes Galmed’s balance sheet, adds goodwill and integration risk, and could accelerate capital needs. This raises structural execution and financing risk during integration and European commercial rollout.
Galmed Pharmaceuticals News
GLMD FAQ
What was Galmed Pharmaceuticals’s price range in the past 12 months?
Galmed Pharmaceuticals lowest stock price was $0.41 and its highest was $2.09 in the past 12 months.
What is Galmed Pharmaceuticals’s market cap?
Galmed Pharmaceuticals’s market cap is $3.95M.
When is Galmed Pharmaceuticals’s upcoming earnings report date?
Galmed Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 7 days.
How were Galmed Pharmaceuticals’s earnings last quarter?
Galmed Pharmaceuticals released its earnings results on May 20, 2026. The company reported -$0.38 earnings per share for the quarter, the consensus estimate of -$0.38 by $0.
Is Galmed Pharmaceuticals overvalued?
According to Wall Street analysts Galmed Pharmaceuticals’s price is currently Overvalued.
Does Galmed Pharmaceuticals pay dividends?
Galmed Pharmaceuticals does not currently pay dividends.
What is Galmed Pharmaceuticals’s EPS estimate?
Galmed Pharmaceuticals’s EPS estimate is -0.39.
How many shares outstanding does Galmed Pharmaceuticals have?
Galmed Pharmaceuticals has 7,684,074 shares outstanding.
What happened to Galmed Pharmaceuticals’s price movement after its last earnings report?
Galmed Pharmaceuticals reported an EPS of -$0.38 in its last earnings report, expectations of -$0.38. Following the earnings report the stock price went up 5.226%.
Which hedge fund is a major shareholder of Galmed Pharmaceuticals?
Currently, no hedge funds are holding shares in GLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
GLMD Stock 12 Month Forecast
Average Price Target
―Technical Analysis
AIM ImmunoTech
―
Jaguar Animal Health
―
Quoin Pharmaceuticals
―
Silo Pharma
―
Calidi Biotherapeutics
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
<0.01% Other Institutional Investors
99.93% Public Companies and
Individual Investors